Kukje Pharma Statistics

Total Valuation

Kukje Pharma has a market cap or net worth of KRW 98.76 billion. The enterprise value is 119.73 billion.

Market Cap	98.76B
Enterprise Value	119.73B

Important Dates

The next estimated earnings date is Monday, March 17, 2025.

Earnings Date	Mar 17, 2025
Ex-Dividend Date	n/a

Share Statistics

Kukje Pharma has 20.36 million shares outstanding. The number of shares has increased by 0.39% in one year.

Current Share Class	n/a
Shares Outstanding	20.36M
Shares Change (YoY)	+0.39%
Shares Change (QoQ)	-1.04%
Owned by Insiders (%)	12.78%
Owned by Institutions (%)	8.45%
Float	12.69M

Valuation Ratios

The trailing PE ratio is 24.00.

PE Ratio	24.00
Forward PE	n/a
PS Ratio	0.66
PB Ratio	1.10
P/TBV Ratio	1.11
P/FCF Ratio	88.13
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.55, with an EV/FCF ratio of 106.85.

EV / Earnings	29.14
EV / Sales	0.80
EV / EBITDA	15.55
EV / EBIT	27.57
EV / FCF	106.85

Financial Position

The company has a current ratio of 2.26, with a Debt / Equity ratio of 0.33.

Current Ratio	2.26
Quick Ratio	1.25
Debt / Equity	0.33
Debt / EBITDA	3.84
Debt / FCF	26.37
Interest Coverage	3.29

Financial Efficiency

Return on equity (ROE) is 5.28% and return on invested capital (ROIC) is 2.51%.

Return on Equity (ROE)	5.28%
Return on Assets (ROA)	1.80%
Return on Capital (ROIC)	2.51%
Revenue Per Employee	615.26M
Profits Per Employee	16.84M
Employee Count	244
Asset Turnover	1.00
Inventory Turnover	3.32

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -27.13% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-27.13%
50-Day Moving Average	5,404.90
200-Day Moving Average	5,463.73
Relative Strength Index (RSI)	40.07
Average Volume (20 Days)	275,878

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kukje Pharma had revenue of KRW 150.12 billion and earned 4.11 billion in profits. Earnings per share was 202.05.

Revenue	150.12B
Gross Profit	78.05B
Operating Income	4.34B
Pretax Income	4.69B
Net Income	4.11B
EBITDA	7.70B
EBIT	4.34B
Earnings Per Share (EPS)	202.05

Full Income Statement

Balance Sheet

The company has 8.60 billion in cash and 29.56 billion in debt, giving a net cash position of -20.96 billion or -1,029.19 per share.

Cash & Cash Equivalents	8.60B
Total Debt	29.56B
Net Cash	-20.96B
Net Cash Per Share	-1,029.19
Equity (Book Value)	89.87B
Book Value Per Share	4,412.86
Working Capital	29.76B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.78 billion and capital expenditures -2.66 billion, giving a free cash flow of 1.12 billion.

Operating Cash Flow	3.78B
Capital Expenditures	-2.66B
Free Cash Flow	1.12B
FCF Per Share	55.03

Full Cash Flow Statement

Margins

Gross margin is 51.99%, with operating and profit margins of 2.89% and 2.74%.

Gross Margin	51.99%
Operating Margin	2.89%
Pretax Margin	3.12%
Profit Margin	2.74%
EBITDA Margin	5.13%
EBIT Margin	2.89%
FCF Margin	0.75%

Dividends & Yields

Kukje Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.39%
Shareholder Yield	-0.39%
Earnings Yield	4.17%
FCF Yield	1.13%

Stock Splits

The last stock split was on March 17, 2023. It was a forward split with a ratio of 1.05.

Last Split Date	Mar 17, 2023
Split Type	Forward
Split Ratio	1.05

Scores

Kukje Pharma has an Altman Z-Score of 2.18. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.18
Piotroski F-Score	n/a